All News
Doctor Appointment Wait TImes are Up
Forbes reports that a recent Merritt Hawkins survey shows that patients are waiting an average of 26 days for a scheduled appointment with a doctor.
Read Article
First In Class, TYK2 Inhibitor FDA Approved for Psoriasis
Deucravacitinib (Sotyktu), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years.
Read Article
COVID Outcomes in Dermatomyositis
A retrospective study of dermatomyositis (DM) patients with COVID-19, shows that DM patients without comorbidities fair well (with regard to mortality and hospitalisation).
Read Article
Does Fibromyalgia Need B12? (9.9.2022)
Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news from RheumNow.com.
Read Article
The ACR is developing a new clinical practice guideline for systemic autoimmune rheumatic disease with interstitial lung disease (ILD). The Call for Public Comment is open until September 29, 2022. https://t.co/UxXDbGEQlh https://t.co/zGoBpbKLTC
Links:
Dr. John Cush RheumNow ( View Tweet)
A longitudinal study of 506 ANCA-associated vasculitis (AAV) pts showed pts w/ negative ANCA serologies within 180 days of induction had signif lower risk of relapse (HR 0.55; 0.38 to 0.81) but not for ESRD or death within 5 years. https://t.co/Dn8GGXnSDi https://t.co/C73hG9T7Au
Links:
Dr. John Cush RheumNow ( View Tweet)
Immunosuppresive (IST; MMF or AZA) withdrawl in 96 stable Lupus Nephritis pts also on HCQ. After 2 years, Relapse occurred in 12.5% w/ IST continued & 27.3% with IST D/C (Not noninferior). Less Severe SLE flares (renal & extrarenal) w/ IST continuation https://t.co/XWmJpkqhG9 https://t.co/gYM24QIiYz
Links:
Dr. John Cush RheumNow ( View Tweet)
COVID Outcomes in Dermatomyositis
A retrospective study of dermatomyositis (DM) patients with COVID-19, shows that DM patients without comorbidities fair well (with regard to mortality and hospitalisation).
https://t.co/nlCVHt3XeS https://t.co/Bhc47k7rMD
Links:
Dr. John Cush RheumNow ( View Tweet)
Does Fibromyalgia Need B12?
Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news.
https://t.co/ztDVHfGegM https://t.co/ux4F0UIIld
Links:
Dr. John Cush RheumNow ( View Tweet)
Spanish SpA Registry (REGISPONSER) - 18.3% had psoriasis; w/ 3/4 of these (76%) having PSO before MSK Sxs. Pts w/ PSO before MSK Sxs had shorter dz duration, lower BMI, Less B27 & anterior uveitis, more dactylitis and ^risk PsA dx (78% vs 56%) https://t.co/xchK5ETmg3 https://t.co/F9klsUE5er
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 130 patients with ITP (w/ 10 later Dx SLE (30 mos F/U). Risk factors for ITP developing SLE included young age (< 40yrs; OR 6.3), organ bleeding (OR 13.7), and ANA (≥ 1:160; OR 6.6) https://t.co/o9sO5WQmcq https://t.co/6RrrKzu41p
Links:
Dr. John Cush RheumNow ( View Tweet)
Voclosporin Efficacy and Safety in Lupus Nephritis
An integrated analysis of two pivotal trials of voclosporin, a calcineurin inhibitor, in lupus nephritis patients saw significant improvement in complete renal responses (CRR) at one year.
https://t.co/WqQ7wdzmCc https://t.co/uxFb6Nbdgi
Links:
Dr. John Cush RheumNow ( View Tweet)
Multicentre matched control study looked at primary Sjogrens that developed lymphoma or NOT. Parotid swelling (PSW) is an early major predictor of non-Hodgkin lymphoma in pSS; esp if present before or dx, & w/ a longer duration of PSW https://t.co/wCyZjRbWe8 https://t.co/U0LlDnuNtZ
Links:
Dr. John Cush RheumNow ( View Tweet)
B12 or Placebo effect? Open label study of B12 (1000mcg/d) in 29 fibromyalgia pts showed after 50d, significant reductions in FM Impact Quest. (FIQR; 49.8 to 40.00; p< 0.01), Function, Sxs, anxiety scores all signif improved. https://t.co/OEJ4RY2EkY https://t.co/afkcIHMYVz
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has approvef deucravacitinib (Sotyktu), an oral TYK2 inhibitor, for use in adults with Moderate-to-Severe Plaque Psoriasis. Approval was based on pivotal Phase 3 POETYK PSO clinical trials demonstrated superior efficacy over PBO & apremilast https://t.co/mkRgVZ0Crh https://t.co/833jGV1yO4
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has approved SPEVIGO® (spesolimab-sbzo) an IV injection - the first-approved treatment option for generalized pustular psoriasis (GPP) FLARES. Spesolimab is an interleukin-36 receptor antagonist. https://t.co/zmuB1tyw9W https://t.co/bJiQB5qJNl
Links:
Dr. John Cush RheumNow ( View Tweet)
Does Fibromyalgia Need B12?
Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news.
https://t.co/NmAQkuBxg1 https://t.co/W89EImXlvE
Links:
Dr. John Cush RheumNow ( View Tweet)
A Rheum & Derm Conversation on Treating PsA and Moderate-to-Severe PsO
Sponsored by Lilly USA
Listen to Drs. Mease and Armstrong discuss a multidisciplinary approach and importantconsiderations when treating patients with joint and
skin concerns.
https://t.co/lTfz2kUr51 https://t.co/mPbe9ZqZ8f
Links:
Dr. John Cush RheumNow ( View Tweet)
How to predict IBD in AS/SpA? Study of 82 SpA pts undergoing colonoscopy showed: Rectal bleeding, diarrhea, abdominal pain, high Dz activity and calprotectin levels were suggestive of abnormal ileum inflammation and risk of IBD https://t.co/10PKp7uwmx https://t.co/tnU5tu6Ffp
Links:
Dr. John Cush RheumNow ( View Tweet)
JAKi inhibit Vaccine responses some - study of 113 RA fully vaccinated pts assess 6wks post 2nd jab - 51 on JAKi and 62 not on JAKi. Pts not on JAK 77.4% had humoral response; 29% less (54.9%) in thos on JAK inhibitors; even more if on MTX + JAKi https://t.co/NtN4XEa2nE https://t.co/0Msto77iUK
Links:
Dr. John Cush RheumNow ( View Tweet)
